Alexion defends move to dismiss EmblemHealth's US claims over Soliris
MLex Summary: Alexion Pharmaceuticals defended its motion to dismiss EmblemHealth's US antitrust claims over the unlawful delay of biosimilar competition for Soliris, saying Emblem's claims over Alexion's patent litigation against Amgen...To view the full article, register now.
Already a subscriber? Click here to view full article